tbuckley/cabot-search huggingface dataset:
Atovaquone for Pneumocystis carinii Pneumonia
Authors: Michael M. Lederman
Journal: Annals of Internal Medicine (1995)

Letters15 February 1995Atovaquone for Pneumocystis carinii PneumoniaMichael M. Lederman and Charles van der HorstMichael M. LedermanSearch for more papers by this author and Charles van der HorstSearch for more papers by this authorAuthor, Article, and Disclosure Informationhttps://doi.org/10.7326/0003-4819-122-4-199502150-00014 SectionsAboutFull TextPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissions ShareFacebookTwitterLinkedInRedditEmail TO THE EDITOR:We are concerned that the article by Dohn and colleagues [1] may have overstated the efficacy of oral atovaquone for the treatment of Pneumocystis carinii pneumonia in patients with the acquired immunodeficiency syndrome (AIDS). The study is described as an equivalency trial, that is, a test of the hypothesis that using oral atovaquone is not worse than using intravenous pentamidine for the treatment of AIDS-associated P. carinii pneumonia. The authors reported that the hypothesis was confirmed; in this small study, treatment failures were not significantly more frequent in the atovaquone group than in the pentamidine group. However, ...REFERENCE1. Dohn MN, Weinberg WG, Torres RA, Follansbee SE, Caldwell PT, Scott JD, et al. Oral atovaquone compared with intravenous pentamidine for Pneumocystis carinii pneumonia in patients with AIDS. Ann Intern Med. 1994; 121:174-80. Google Scholar Author, Article, and Disclosure InformationAuthors: Michael M. Lederman; Charles van der Horst PreviousarticleNextarticle Advertisement FiguresReferencesRelatedDetails Metrics Cited byAtovaquoneANTIPROTOZOAL AND ANTIHELMINTHIC DRUGSAtovaquone 15 February 1995Volume 122, Issue 4Page: 314-315KeywordsAIDSAtovaquonePneumocystis carinii pneumoniaPneumonia ePublished: 15 August 2000 Issue Published: 15 February 1995 Copyright & PermissionsCopyright © 1995 by American College of Physicians. All Rights Reserved.PDF downloadLoading ...
Effects of Acidification on the Mobility of Metals and Metalloids: An Overview
Authors: J. M. Wood
Journal: Environmental Health Perspectives (1985)

The exchange rates for metals and metalloids between sediments, soils, water and aquatic biota are discussed in terms of normal and acidified ecosystems. Where it is possible, the pathways for a number of toxic elements are presented with special emphasis on the impact of acidification on changing chemical speciation, and on the potential toxicity of such acid-generated chemical species. Concerns for the impact of acidification on the stability of ecosystems, the safety of drinking water, bioaccumulation in fish and in plants are addressed.
Immune response results from vesigenurtacel-l (HS-410) in combination with BCG from a randomized phase 2 trial in patients with non-muscle invasive bladder cancer (NMIBC).
Authors: Gary D. Steinberg, Neal D. Shore, Lawrence Ivan Karsh, James L. Bailen, Trinity Bivalacqua, Karim Chamie, James S. Cochran, Richard David, Robert L. Grubb, Wael A. Harb, Jeffrey M. Holzbeierlein, Ashish M. Kamat, Edouard John Trabulsi, William Vincent Walsh, Michael Brandon Williams, Fredrick Wolk, Michael Woods, Melissa Leigh Price, Brandon Early, Taylor Houghton Schreiber
Journal: Journal of Clinical Oncology (2017)

4531 Background: Vesigenurtacel-L (HS-410) is a vaccine comprised of an allogeneic cell line, selected for high expression from a series of bladder tumor antigens, and transfected with gp96-Ig. Cell-secreted gp96-Ig delivers these cell-derived antigens to a recipient's own antigen presenting cells, activating CD8+ cytotoxic T cells. Here we present the secondary immune outcomes from a randomized Phase 2 trial with HS-410 in combination with BCG in NMIBC. Trial ID NCT02010203. Methods: 78 patients with intermediate- (n = 5) or high-risk (n = 73) NMIBC who are either BCG-naïve or recurrent, with or without carcinoma in situ (CIS), were enrolled 1:1:1 to one of two doses of HS-410 (either 10 6 or 10 7 cells/dose) or placebo in combination with 6 weeks of induction BCG, followed by 6 more weeks of HS-410 in the induction phase. Maintenance treatment consisted of 3-weekly treatments at the following timepoints: 3 mo., 6 mo., 12 mo. Concurrently, 16 patients (1 int. risk, 15 high-risk) were enrolled in an open-label monotherapy HS-410 arm for patients who did not receive BCG. The primary endpoint was 1-year RFS. Secondary immune evaluations include ELISPOT, tumor IHC, tumor antigen profiling, flow cytometry, urine cytokine analysis, and T cell receptor sequencing. Results: HS-410 treatment was well tolerated; AE profiles were similar across the treatment arms. HS-410 antigen expression showed prominent overlap with patient tumors. IFNγ ELISPOT assay demonstrated a high baseline response to HS-410; responses to overlapping peptide pools of HS-410 derived antigens defined immune responders (doubling of IFNγ-secreting cells). IHC demonstrated that ~60% of NMIBC patient tumor biopsies were TIL negative at baseline (n = 84), but that only ~15% of tumor biopsies were TIL negative post treatment (n = 40). Thus, TIL status may be used to define a responder and non-responder population to HS-410. Conclusions: Vesigenurtacel-L is well-tolerated, and immunologic responses consistent with vaccine mechanism of action may correlate with efficacy and suggest future biomarkers. Vesigenurtacel-L warrants further investigation as a potential treatment for NMIBC. Clinical trial information: NCT02010203.
Partial Characterization of a Fetal Lung Antigen associated With Human Bronchogenic Carcinoma
Authors: E. Sega, Yongock Cho
Journal: JNCI Journal of the National Cancer Institute (1979)

The Initial stage of metastasis formation, l.e., the entry of metastatic cells from a malignant subcutaneously growing myelogenous tumor into the circulation, was observed by means of transmission electron microscopy and scanning electron microscopy in Long-Evans rats. The transmural passage of malignant cells occurred through the walls of intact venules within the tumor. The malignant cell penetrated the endothelial cell body by making a temporary migration pore. The migration pore closed after the malignant cell entered the vascular lumen. The endothelial vascular lining remained continuous. The entry of malignant cells Into the circulation was not the result of the general invasive and destructive properties of malignant tumor cells, but the consequence of a specific action of the tumor cells on the ablumlnal plasma membrane of the endothellum.
Meningitis from a pneumococcus moderately resistant to penicillin
Authors: J. C. Gartner
Journal: JAMA (1979)

Strains of pneumococci moderately resistant to penicillin were recovered from three patients at the Children's Hospital of Pittsburgh during 1978. One of these children had meningitis and showed signs of early relapse despite high doses of penicillin G potassium. Routine screening of pneumococci for penicillin resistance is recommended.
Psychopaths
Authors: G. C. F. Roe
Journal: BMJ (1957)

<h3>Background</h3> HSP is characterised by spasticity and progressive gait impairment. There’s no reliable way to monitor gait deterioration during clinics. Optoelectronic systems have demonstrated differing characteristics between gait of HSP patients and controls. They’re expensive and impractical for use in clinic settings. Inertial sensors haven’t been used to characterise HSP gait <h3>Objectives</h3> Study use of inertial sensors to identify gait characteristics that differentiate mild HSP patients from controls. To identify a gait based biomarker which can be used to monitor disease progression in a longitudinal study. <h3>Methods</h3> Neurological examination, SPRS, Modified Ashworth score, brief pain inventory were undertaken. Instrumented timed up and go (iTUG) and instrumented 10 metre walk tests (i10) wearing an inertial sensor during clinic appointments at 6 month intervals. <h3>Results</h3> Gait variables differentiating between patients and controls, including those with mild disease, were identified. Parameters differentiating between patients with SPG4 and SPG7 mutations were found. 8 patients were re-assessed after 6 months. Analysis did not show gait deterioration. <h3>Conclusion</h3> Inertial sensors can detect differences between HSP patients and controls, including those mildly affected. They can also differentiate between patients with different mutations. Further follow up data is needed to assess whether inertial sensors can predict future gait deterioration.
Serum bile acid species are associated with liver fibrosis and clinical disease progression in patients with primary sclerosing cholangitis
Authors: Michael Trauner, Kris V. Kowdley, Atsushi Tanaka, Jun Xu, Ya Wang, Guang Chen, Andrew Billin, Chuhan Chung, Robert Myers, Zachary Goodman, Andrew Muir, Michael P. Manns, Douglas Thorburn, Cynthia LEVY, Christopher Bowlus
Journal: Journal of Hepatology (2020)
Left atrial thrombus in a 10-month-old boy ? successful thrombolysis with recombinant tissue-type plasminogen activator after open-heart surgery: review of the literature
Authors: H. G. Kehl, D. Kececioglu, H. Vielhaber, S. Kotthoff, M. Weyand, G. Jorch, J. Vogt, U. Nowak-G�ttl
Journal: Intensive Care Medicine (1996)
The 'Growth Disease' in American Institutional Medicine-Reply
Authors: Albert J. Miller
Journal: JAMA (1982)

<h3>In Reply.—</h3> Dr McLaughlin uses some words to paraphrase my COMMENTARY ("bewails," "aggressive," "power by default") that suggest more rancor than I intended. My aim was to urge some hospital governing board reforms that are long overdue. Of course there is "danger" in adding more physicians to such boards, but physicians should be held responsible for the caliber of the medical care at institutions where they work and should be charged with appropriate responsibility. Certainly they will have vested interests, but Dr McLaughlin obviously is keenly aware of the vested interests that nonphysician board members also have. Conflicts of interest do lead to undue pressure on administrators, but fortunately such self-serving board members are not too common. Dr McLaughlin fails to discuss the conflicts of interest of administrators, who also may be self-serving and manipulative of board and medical staff members. I wonder if that is not more frequent than
Older adults’ preferred and perceived roles in decision making about palliative chemotherapy: Their decision priorities, and information preferences.
Authors: Erin Moth, Belinda Emma Kiely, Andrew James Martin, Vasi Naganathan, Stephen A. Della-Fiorentina, Florian Honeyball, Rob Zielinski, Christopher B. Steer, Hiren A. Mandaliya, Abi Ragunathan, Prunella Blinman
Journal: Journal of Clinical Oncology (2019)

11546 Background: We sought older adults’ preferred and perceived roles in decision-making about palliative chemotherapy; their decision-making priorities; and information received and desired. Methods: Patients aged ≥65 years with incurable cancer who had discussed palliative chemotherapy with an oncologist and made a decision about whether or not to receive palliative chemotherapy were invited to complete a written questionnaire. Preferred and perceived decision-making roles were assessed by the Control Preferences Scale (CPS). Associations with preferred decision-making role were examined using Wilcoxon rank sum tests. Factors important in making a decision about chemotherapy, and receipt of and desire for information were described. Results: The 179 respondents had a median age of 74 years (range 65 to 92 years). Most were male (114, 64%) and had chosen to receive chemotherapy (148, 83%). Half (92, 52%) were vulnerable by the Vulnerable Elders Survey-13 (score ≥3). Preferred decision-making roles (n = 173) were active in 39%, collaborative in 27%, and passive in 35%. Perceived decision-making roles (n = 172) were active in 42%, collaborative in 22%, and passive in 36%, and matched the preferred role for 63% of patients. Preference for an active role was associated with being single/widowed (p = 0.004, OR 1.49) and declining chemotherapy (p = 0.02, OR 2). Factors ranked most important when making a decision about chemotherapy (n = 159) were “doing everything possible” (30%), “my doctor’s recommendation” (26%), “my quality of life” (20%), and “living longer” (15%). A minority expected chemotherapy to cure their cancer (14%). Most had discussed expectations of cure (70%), side effects (88%) and benefits (82%) of chemotherapy, though fewer had received quantitative prognostic information (49%) than desired this (67%). Conclusions: Older adults showed varied preferences for involvement in decision-making about palliative chemotherapy, and most played the role that they preferred. To facilitate shared decision-making, oncologists should seek patients’ decision-making preferences, priorities and information needs when discussing palliative chemotherapy.
Medical News
Journal: JAMA (1971)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
LEGISLATION TO PREVENT THE SALE OF UNDRAWN POULTRY.
Journal: JAMA (1906)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Survival Techniques
Authors: Carly Benner Zapata
Journal: JAMA (2018)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
THE COST OF A DISEASE
Journal: JAMA (1965)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
The epidemiology of gallstone disease in Rome, Italy. Part I. Prevalence data in men
Journal: Hepatology (1988)

A population of male civil servants in Rome, Italy, was investigated to determine the prevalence of symptomatic and asymptomatic gallstone disease. Field activities started in December, 1982 and were concluded in July, 1984. Diagnosis was made using real-time ultrasonography. Participation in the study was 71.5%. Prevalence of gallstone disease was 8.2% and increased with age from 2.3% in the 20- to 25-year-old age group to 14.4% in the 60- to 69-year-old age group, based on both presence of gallstones and history of cholecystectomy. About one-third of the subjects with gallstone disease had previously been submitted to cholecystectomy. Only 7.7% of the subjects with presence of gallstones complained of at least one episode of biliary pain in the preceding 5 years. Frequency of “minor” dyspeptic symptoms was not different between men with and those without gallstones.
BOOK REVIEWS
Authors: C. M. BROOME, L. L. LESSIN
Journal: JNCI Journal of the National Cancer Institute (1992)

BOOK REVIEWS Get access Hematology: Basic Principles and Practice Ronald Hoffman , Edward J. Benz , Sanford J. Shattil , Bruce Furie , Harvey J. Cohen , eds. New York : Churchill Livingstone , 1991 . 1919 pp., illus. $110. CATHERINE M. BROOME, CATHERINE M. BROOME Division of Hematology/Oncology George Washington University Medical Center2150 Pennsylvania Ave., N.W. Washington, DC 20037 Search for other works by this author on: Oxford Academic PubMed Google Scholar LAWRENCE L. LESSIN LAWRENCE L. LESSIN Division of Hematology/Oncology George Washington University Medical Center2150 Pennsylvania Ave., N.W. Washington, DC 20037 Search for other works by this author on: Oxford Academic PubMed Google Scholar JNCI: Journal of the National Cancer Institute, Volume 84, Issue 4, 19 February 1992, Page 268, https://doi.org/10.1093/jnci/84.4.268-a Published: 19 February 1992
Fillers
Authors: R. Robinson
Journal: BMJ (1995)

methods used in these studies and rejects those whose conclusions are likely to be invalid or inapplicable.The selected articles are then described on one page, beginning with an abstract that is structured and rewrittenbecause many abstracts published in the original journals do not include essential information.8Each abstract is accompanied by a commentary from an expert in the subject who integrates it with other evidence and draws out the messages for practice.The articles cover the prevention, cause, and course of disease; screening; diagnosis; treatment; and rehabilitation; there are also studies of the economic aspects and quality of care and of strategies for improving the education and performance of doctors.The results of this process are dramatic and cheering.The 6000 original articles on internal medicine published each year in general journals are distilled to 300, and each article is on one page rather than four or five.Thus, even a doctor with a broadly based clinical practice can keep up with the latest important advances in clinical research by reading a page a day, and still have days to spare.Not surprisingly ACP J7ournal Club has a high readership and is found extremely useful by its readers.Now the American College of Physicians and the BMJ Publishing Group are to collaborate to publish Evidence Based Medicine, a development of ACP Journal Club.This will include some abstracts and commentaries published in ACP Journal Club but will also include new ones.These will come from the subspecialties of general medicine and from general practice, paediatrics, surgery, obstetrics and gynaecology, psychiatry, public health, and the parts of anaesthetics-for instance, the management of pain-that are common to much of medicine.Preference will be given to studies that cover conditions-like diabetes and depression-that are common and encountered in all specialties.Evidence Based Medicine will also publish systematic reviews of the effects of health care from the Cochrane Collaboration, selected reports from the York Centre for Reviews and Dissemination, educational material describing how to practise evidence based medicine, and editorials of general interest.Full information on subscribing to the new journal, which will be launched in October 1995, is available in the advertisement in this week's BMJ.* ACP Journal Club and Evidence Based Medicine will publish the gold that intellectually intense processes will mine from the ore of about 100 of the world's top journals.Doctors owe it to themselves and their patients to make sure that they keep up with what is new and important.
Acute herpes zoster: sympathetic nerve block unsupported by prospective trial
Authors: J. P. McGuinness
Journal: JAMA (1993)

<h3>To the Editor.</h3> —The article by Dr Straus<sup>1</sup>provides an excellent review of acute herpes zoster; however, in his discussion of treatment, I believe that an important modality was omitted. Bonica and Buckley<sup>2</sup>reported that sympathetic nerve blocks, if initiated early enough in the course of the condition, will decrease both the duration and the severity of the herpetic eruption and accelerate healing. The sympathetic nerve blocks also provide rapid diminution of pain which is, as Straus aptly points out, the "most menacing aspect of zoster." Bonica and Buckley also suggested that the early use of sympathetic nerve blocks will decrease the incidence of postherpetic neuralgia. The sympathetic nerve blocks should be combined with antiviral drugs. A number of treatment regimes have been described, but the best results are obtained with early intervention. Although the use of sympathetic nerve blocks has been criticized for lack of controlled data,